BAX
33
-3
PFE
25
-3
R
68
-4
IR
65
-6
MAC
68
4
FRT
41
-4
UHS
56
-2
VLO
39
-4
V
70
-6
PX
62
-4
CHD
47
-6
SE
65
2
KEY
37
-3
PBI
63
-3
EIX
69
-3
VRSK
73
-7
PSX
50
-2
ORCL
54
3
DE
62
-3
STX
45
-11
BAX
33
-3
PFE
25
-3
R
68
-4
IR
65
-6
MAC
68
4
FRT
41
-4
UHS
56
-2
VLO
39
-4
V
70
-6
PX
62
-4
CHD
47
-6
SE
65
2
KEY
37
-3
PBI
63
-3
EIX
69
-3
VRSK
73
-7
PSX
50
-2
ORCL
54
3
DE
62
-3
STX
45
-11
Financhill
Back

PTC Therapeutics 10K Form

Buy
51

PTCT
PTC Therapeutics

Last Price:
50.29
Seasonality Move:
17.12%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-04-25 10Q PTCT/PTC Therapeutics Quarterly
2023-10-26 10Q PTCT/PTC Therapeutics Quarterly
2023-08-03 10Q PTCT/PTC Therapeutics Quarterly
2023-04-27 10Q PTCT/PTC Therapeutics Quarterly
2022-10-27 10Q PTCT/PTC Therapeutics Quarterly
2022-08-04 10Q PTCT/PTC Therapeutics Quarterly

Receive PTCT News And Ratings

See the #1 stock for the next 7 days that we like better than PTCT

PTCT Financial Statistics

Sales & Book Value

Annual Sales: $937.82M
Cash Flow: $-87.77M
Price / Cash Flow: 0
Annual Sales: $-13.70
Price / Book: 0

Profitability

EPS (TTM): -5.94000
Net Income (TTM): $-453.2M
Gross Margin: $872.34M
Return on Equity: 0%
Return on Assets: -26.04%

PTC Therapeutics Earnings Forecast

Key PTC Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for PTCT is 93.02%.
  • The Selling, General & Administrative Expenses for PTCT have been equal to 35.46% of Gross Profit Margin.
  • The Research & Development expenses have been 71.08% of Revenue.
  • The Interest Expense is -20.62% of Operating Income.
  • The Net Earning history of PTCT is -66.81% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 4 years.

PTC Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PTCT
CUSIP: 69366J
Website: ptcbio.com

Debt

Debt-to-Equity Ratio: -0.27
Current Ratio: 2.1
Quick Ratio: 1.99

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PTCT Technical Analysis vs Fundamental Analysis

Buy
51
PTC Therapeutics (PTCT) is a Buy

Is PTC Therapeutics a Buy or a Sell?

  • PTC Therapeutics stock is rated a Buy
    The current PTC Therapeutics [PTCT] share price is $50.29. The Score for PTCT is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.